1Mayo Clinic and Foundation, Rochester, MN, USA; 2University of Pennsylvania School of Medicine; 3University
of California at San Francisco

MRI and CSF biomarkers that closely reflect the
underlying biology add value to clinical assessment as well as to the
understanding of mechanisms underlying Alzheimers disease (AD). Our objective
was to assess the correlations of both MRI and cerebro spinal fluid (CSF)
biomarkers with clinical diagnosis and cognitive performance at baseline, and
also assess the ability of these disease indicators to predict future cognitive
decline. We examined these questions using data from the Alzheimers disease
Neuroimaging Initiative (ADNI) study which consists of a large database of
cognitively normal (CN), amnestic mild cognitive impairment (aMCI) and AD with
both CSF and MRI.